ReviewNatural selection in neoplastic progression of Barrett's esophagus
Section snippets
Natural selection in neoplastic progression
A neoplasm is a microcosm of evolution. This fact lies at the heart of why we get cancer and why it has been so hard to cure. Within a neoplasm, mutant clones compete for space and resources [1], [2], [3], [4], [5]. Those that have a competitive advantage and are more aggressive will tend to spread in the neoplasm until a mutation produces an invasive phenotype and the neoplasm becomes malignant. Therapies add a new selective force to the neoplasm and tend to select for resistance [6], [7], [8]
Parameters of the rate of evolution
If neoplastic progression is an evolutionary process, then the rate of evolution should be associated with the rate of progression to cancer. Evolution is traditionally and most narrowly defined as changes in allele frequencies. There are three parameters that determine the rate of evolution in a neoplasm: (1) mutation rate, (2) population size, and (3) strength of selection. The faster that new mutations accumulate in a neoplasm, the faster the neoplasm will acquire all the necessary
Barrett's esophagus as a model of clonal evolution in neoplastic progression
Nowell's hypothesis of clonal evolution in neoplastic progression should apply to all neoplasms. However, it has been difficult to study in most neoplasms because either the pre-cursor lesions are not easily identified, or if they are identified, they are removed and so cannot be studied longitudinally to see how the clones evolve. Barrett's esophagus (BE) is an exception.
BE is a pre-malignant neoplastic [20] condition of the esophagus, that is the only known precursor of esophageal
Mutation rate
Mutation rates are difficult to study in humans in vivo. Most estimates of mutation rates either come from cell culture [34], [35] or the big blue mouse [36]. However, there is no doubt that BE neoplastic cells have higher mutation rates than normal tissue because a variety of genetic and epigenetic lesions have been observed in BE at higher frequencies than are observed in normal tissues.
Allelotype studies, using a sparse set of microsatellite markers scattered across the genome, have found
Population size
The size of a population is a fundamental constraint on the rate at which it can accumulate mutations and evolve. Until the mid 1970s, there were reports of BE segments growing over time [58], [59], [60]. However, since that time, such reports have virtually disappeared [61]. It may not be a coincidence that H2 blockers, the first effective acid suppression medications, were introduced in the mid 1970s. Today, in the vast majority of cases, the length of the Barrett's segment remains stable
Strength of selection
The strength of selection on a particular allele is best measured by the rate at which it spreads through a population. This has been difficult to measure in most neoplasms for two reasons: very few neoplasms can be tracked over time and few investigators have measured the frequency of alleles within a neoplasm by assaying multiple biopsies [20], [68].
The close association between gastroesophageal reflux and the etiology of BE suggests that under the abnormal environment of reflux, BE cells
Open problems
Neoplastic evolution is probably better understood in BE than any other human solid neoplasm, and is summarized in Fig. 1. However, there are many unsolved mysteries that require further study.
Conclusions
Barrett's esophagus has proven a fruitful model system of human neoplastic progression in which to test Nowell's hypothesis in vivo. All of the necessary components of natural selection in a neoplasm have been confirmed in BE including somatic variation, heritability of that variation, and differences in relative fitness of the clones due to that variation. The introduction of evolutionary theory to cancer biology provides a useful set of quantitative analyses and explanations for neoplastic
Acknowledgements
This work was supported by NIH grants P01 CA91955 and K01 CA89267-02. Thanks to Thomas Paulson for helpful comments and suggestions.
References (115)
- et al.
Genetic predisposition and somatic diversification in tumor development and progression
Adv Cancer Res
(2001) Cytogenetic heterogeneity: its role in tumor evolution
Cancer Genet Cytogenet
(1986)- et al.
The resistance phenotype in the development and treatment of cancer
(2000) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Hallmarks of cancer progression in Barrett's oesophagus
Lancet
(2002) Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus
Am J Gastroenterol
(2002)- et al.
Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data
Gastroenterology
(1999) - et al.
Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
Gastroenterology
(1987) - et al.
A hospital's annual rate of esophagectomy influences the operative mortality rate
J Gastrointest Surg
(1998) - et al.
Is there publication bias in the reporting of cancer risk in Barrett's esophagus
Gastroenterology
(2000)
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West
Gastroenterology
Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens
Mod Pathol
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia–dysplasia–carcinoma sequence
Am J Pathol
Loss of heterozygosity associated with uniparental disomy in breast carcinoma
Mod Pathol
Barrett syndrome
Case Reports
The columnar-lined esophagus (Barrett syndrome)—an acquired condition
Gastroenterology
Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas
J Thorac Cardiovasc Surg
Barrett's esophagus: age, prevalence, and extent of columnar epithelium
Gastroenterology
Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma
Am J Gastroenterol
p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus
Gastroenterology
Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
Gastroenterology
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables
Am J Gastroenterol
Is neoadjuvant therapy the answer to adenocarcinoma of the esophagus
Am J Surg
Surveillance and survival in Barrett's adenocarcinomas: a population-based study
Gastroenterology
Endoscopic surveillance of Barrett's esophagus
J Thorac Cardiovasc Surg
Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus
Clin Gastro Hep
Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus
Gastrointest Endosc
Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy
Gastroenterology
Barrett's metaplasia
Lancet
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
Gastroenterology
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
Am J Gastroenterol
Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae
Exp Mol Pathol
Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions
Cancer Genet Cytogenet
DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma
Cancer Genet Cytogenet
Genetic divergence in the clonal evolution of breast cancer
Cancer Res
Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma
Cancer Res
Metapopulation dynamics and spatial heterogeneity in cancer
Proc Natl Acad Sci USA
Roots of clinical resistance to STI-571 cancer therapy
Science
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Science
Multidrug resistance in cancer: role of ATP-dependent transporters
Nat Rev Cancer
Drug resistance: resisting arrest
Nat Rev Cancer
Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention
J Hematother Stem Cell Res
The genetic basis of resistance to cancer chemotherapy
Ann Med
Natural selection in the wild
The clonal evolution of tumor cell populations
Science
Mutator phenotype may be required for multistage carcinogenesis
Cancer Res
The mutation rate and cancer
Proc Natl Acad Sci USA
Multistage carcinogenesis and the incidence of human cancer
Genes Chromosomes Cancer
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus
Cancer Res
Reflux Barrett's oesophagus and adenocarcinoma: burning questions
Nat Rev Cancer
Cited by (44)
α Cell-Specific Men1 Ablation Triggers the Transdifferentiation of Glucagon-Expressing Cells and Insulinoma Development
2010, GastroenterologyCitation Excerpt :Nevertheless, epithelial-to-mesenchymal transition, a form of transdifferentiation, plays an important role in cancer formation and progression.36 Squamous metaplasia, seen in breast and prostate cancers, and other forms of metaplasia observed in esophageal and stomach cancers are well-known precancerous lesions.37 However, the transdifferentiation between different hormone-secreting cell types has never been experimentally established in the framework of endocrine tumors.
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer
2023, Genome BiologySynthesis of Silver Nano Particles Using Myricetin and the In-Vitro Assessment of Anti-Colorectal Cancer Activity: In-Silico Integration
2022, International Journal of Molecular SciencesGenomic hallmarks of cellular dormancy in cancer and therapeutic implications
2021, Research SquareScreening of Barrett's esophagus: Rational, current concepts and perspectives
2021, Tumor Diagnostik und Therapie